Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and early ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

It’s easy to blame swollen fingers on heat or a salty meal — but sometimes, your body might be alerting you to something far ...

Please provide your email address to receive an email when new articles are posted on . For adults with bronchiectasis, $82,545 was the highest annual health care cost observed in a systematic review.

The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Bronchiectasis develops early in the course of cystic fibrosis, being detectable in infants as young as 10 weeks of age, and is persistent and progressive. We sought to determine risk factors for the ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

Please provide your email address to receive an email when new articles are posted on . Patients in this subgroup participated in the phase 3 ASPEN trial. Brensocatib given as 10 mg or 25 mg performed ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...